Norway Artificial Intelligence (AI) in Diagnostics Market Report 2022 to 2030

Norway Artificial Intelligence (AI) in Diagnostics Market Analysis

$ 3999

Norway's Artificial Intelligence (AI) in the diagnostics market is projected to grow from $xx Bn in 2022 to $xx Bn by 2030, registering a CAGR of xx% during the forecast period of 2022-30. The market will be driven by the growing burden of chronic diseases and the rising investments by private startups. The market is segmented by component & by diagnosis. Some of the major players include IBM Watson Health, Siemens Healthineers & Oivi.

ID: IN10NODH002 CATEGORY: Digital Health GEOGRAPHY: Norway AUTHOR: Vidhi Upadhyay

Buy Now

Norway Artificial Intelligence (AI) in Diagnostics Market Executive Summary

Norway's Artificial Intelligence (AI) in the diagnostics market is projected to grow from $xx Bn in 2022 to $xx Bn by 2030, registering a CAGR of xx% during the forecast period of 2022 - 2030. Norway has one of the greatest healthcare systems in the world. Throughout the nation, it comprises both government and private hospitals. Four Regional Health Authorities (RHA) supervise the operation of public hospitals, which are controlled by the Ministry of Health and Care Services. The government extensively subsidizes the country's universal healthcare system through taxation. In Norway, 36 998 new cancer cases were reported in 2021. Coronary Heart Disease Deaths in Norway reached 5,321 in 2020, accounting for 15.60% of total fatalities, according to WHO statistics.

In Norway, AI is used in diagnosis in a variety of fields, including radiology, pathology, and cardiology. AI-based diagnostic tools, for example, are being developed to scan medical imaging and detect anomalies, such as malignant lesions or brain bleeds, with improved accuracy and speed. AI is also being used to assist healthcare practitioners in analyzing massive volumes of medical data in order to detect patterns and risk factors for specific diseases.

There are various Norwegian firms developing AI-based diagnostic tools, including both established players and startups. GE Healthcare, Philips, and Siemens Healthineers are among the leading companies. Some Norwegian businesses such as Oivi, MedSeg & Diatec Monoclonals are also creating AI-based diagnostic solutions.

Market Dynamics

Market Growth Drivers

The Norwegian health system has introduced electronic health records (EHRs) and is trying to digitize and make medical records more accessible to healthcare professionals. This data may be utilized to increase diagnostic accuracy and efficiency by training AI algorithms and models. Apart from the increasing availability of digital health data, the increasing demand for healthcare services due to the aging population and the growing burden of chronic diseases also play a huge role in driving the AI Diagnostics market expansion.

Market Restraints

The Norwegian healthcare system is heavily regulated, and new technology must meet severe approval and deployment criteria. Because of concerns regarding safety and efficacy, AI-based diagnostic systems may face regulatory obstacles. Although the Norwegian healthcare system has embraced electronic health records (EHRs) and other digital health tools, interoperability across various systems remains restricted. Moreover, privacy concerns, limited access to data, and high acquisition cost are some of the main challenges that need to be addressed in order to realize the full potential of AI in diagnostics in Norway.

Competitive Landscape

Key Players

GE Healthcare
IBM Watson Health
Siemens Healthineers
Philips Healthcare
Google Health
AliveCor, Inc.
MedSeg (NOR)
Diatec Monoclonals (NOR)
Oivi (NOR)

Healthcare Policies and Regulatory Landscape and Reimbursement Scenario

The Ministry of Health and Care Services is the regulatory power (HOD). The Norwegian Medicines Agency (NoMA), a subordinate of HOD, is the federal entity with competence in both medicinal goods and the regulation and monitoring of medical devices. The Blue Prescription Regulation mandates that the government, through the National Insurance Scheme, compensate for a large portion of the costs of medicines, and medical supplies, such as medical devices, required for the treatment of serious illnesses or other risk factors that are likely to induce or worsen serious illness, and where there is a necessity or risk of repeated treatment over a long period of time.

1. Executive Summary
1.1 Digital Health Overview
1.2 Global Scenario
1.3 Country Overview
1.4 Healthcare Scenario in Country
1.5 Digital Health Policy in Country
1.6 Recent Developments in the Country

2. Market Size and Forecasting
2.1 Market Size (With Excel and Methodology)
2.2 Market Segmentation (Check all Segments in Segmentation Section)

3. Market Dynamics
3.1 Market Drivers
3.2 Market Restraints

4. Competitive Landscape
4.1 Major Market Share

4.2 Key Company Profile (Check all Companies in the Summary Section)

4.2.1 Company
4.2.1.1 Overview
4.2.1.2 Product Applications and Services
4.2.1.3 Recent Developments
4.2.1.4 Partnerships Ecosystem
4.2.1.5 Financials (Based on Availability)

5. Reimbursement Scenario
5.1 Reimbursement Regulation
5.2 Reimbursement Process for Diagnosis
5.3 Reimbursement Process for Treatment

6. Methodology and Scope

Artificial Intelligence (AI) in Diagnostics Market Segmentation

By Component Outlook Type (Revenue, USD Billion):
- Software
- Hardware
- Services

By Diagnosis Outlook Type (Revenue, USD Billion):
- Cardiology
- Oncology
- Pathology
- Radiology
- Chest and Lung
- Neurology
- Others

Methodology for Database Creation

Our database offers a comprehensive list of healthcare centers, meticulously curated to provide detailed information on a wide range of specialties and services. It includes top-tier hospitals, clinics, and diagnostic facilities across 30 countries and 24 specialties, ensuring users can find the healthcare services they need.

Additionally, we provide a comprehensive list of Key Opinion Leaders (KOLs) based on your requirements. Our curated list captures various crucial aspects of the KOLs, offering more than just general information. Whether you're looking to boost brand awareness, drive engagement, or launch a new product, our extensive list of KOLs ensures you have the right experts by your side. Covering 30 countries and 36 specialties, our database guarantees access to the best KOLs in the healthcare industry, supporting strategic decisions and enhancing your initiatives.

How Do We Get It?

Our database is created and maintained through a combination of secondary and primary research methodologies.

1. Secondary Research

With many years of experience in the healthcare field, we have our own rich proprietary data from various past projects. This historical data serves as the foundation for our database. Our continuous process of gathering data involves:

Analyzing historical proprietary data collected from multiple projects.
Regularly updating our existing data sets with new findings and trends.
Ensuring data consistency and accuracy through rigorous validation processes.

With extensive experience in the field, we have developed a proprietary GenAI-based technology that is uniquely tailored to our organization. This advanced technology enables us to scan a wide array of relevant information sources across the internet. Our data-gathering process includes:

Searching through academic conferences, published research, citations, and social media platforms
Collecting and compiling diverse data to build a comprehensive and detailed database
Continuously updating our database with new information to ensure its relevance and accuracy

2. Primary Research

To complement and validate our secondary data, we engage in primary research through local tie-ups and partnerships. This process involves:

Collaborating with local healthcare providers, hospitals, and clinics to gather real-time data.
Conducting surveys, interviews, and field studies to collect fresh data directly from the source.
Continuously refreshing our database to ensure that the information remains current and reliable.
Validating secondary data through cross-referencing with primary data to ensure accuracy and relevance.

Combining Secondary and Primary Research

By integrating both secondary and primary research methodologies, we ensure that our database is comprehensive, accurate, and up-to-date. The combined process involves:

Merging historical data from secondary research with real-time data from primary research.
Conducting thorough data validation and cleansing to remove inconsistencies and errors.
Organizing data into a structured format that is easily accessible and usable for various applications.
Continuously monitoring and updating the database to reflect the latest developments and trends in the healthcare field.

Through this meticulous process, we create a final database tailored to each region and domain within the healthcare industry. This approach ensures that our clients receive reliable and relevant data, empowering them to make informed decisions and drive innovation in their respective fields.